Abstracts tagged "COVID-19"

Abstract Number: 1550 • ACR Convergence 2021
Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
Anna Carbone, Gentiana Vukatana, Enrica Vandelli, Marica Trevisani, Elisa Rossi, Rita Mulè and Marco Fusconi, Rheumatology Unit, Azienda Ospedaliero-Universitaria Bologna, Bologna, Italy
Background/Purpose: There is increasing interest in the safety of COVID-19 vaccination in patients with underlying chronic conditions. We investigated the rates of side effects and/or…
Abstract Number: 1591 • ACR Convergence 2021
Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)
Marco Garrido-Cumbrera¹, Helena Marzo-Ortega², Laura Christen³, José Correa-Fernández⁴, Sergio Sanz-Gomez⁴, Pedro Plazuelo-Ramos⁵, Laurent Grange⁶, Dale Webb⁷, Shantel Irwin⁸, Clare Jacklin⁹, Souzi Makri¹⁰, Elsa Frazão Mateus¹¹, Serena Mingolla¹², Katy Antonopoulou¹³ and Victoria Navarro-Compán¹⁴, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁵Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁶French League Against Rheumatism (AFLAR), Echirolles, France, ⁷National Axial Spondyloarthritis Society (NASS), London, United Kingdom, ⁸Arthritis Action, London, United Kingdom, ⁹National Rheumatoid Arthritis Society (NRAS), London, United Kingdom, ¹⁰Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ¹¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹²Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Bari, Italy, ¹³Hellenic League Againts Rheumatism (ELEANA), Athens, Greece, ¹⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The COVID-19 pandemic has impacted wellbeing of patients with Rheumatic and Musculoskeletal Diseases (RMDs). The aim is to assess wellbeing its associated factors in…
Abstract Number: 1608 • ACR Convergence 2021
Sources of Information About SARS-CoV-2 Used by Patients with Chronic Inflammatory Rheumatic Diseases (CIRD)
Ioana Andreica, Iulia Roman, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) may be at increased risk of Corona Virus Disease 2019 (COVID-19).1 The quality of information obtained plays…
Abstract Number: 1843 • ACR Convergence 2021
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Jessica Gordon¹, Kimberly Showalter¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
Abstract Number: 0003 • ACR Convergence 2021
Clinically Identifiable Autoreactivity Is Common in Severe SARS-CoV-2 Infection
Richard Ramonell¹, Matthew Woodruff², Mark Rudolph³, F. Eun-Hyung Lee¹ and Iñaki Sanz⁴, ¹Emory University, Atlanta, GA, ²Emory University, Decatur, GA, ³Exagen Inc., Vista, CA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: A massive expanson of plasmablasts or antibody secreting cells (ASC) have been shown in severe patients with SARS-CoV-2 infection and in patients with autoimmune…
Abstract Number: 0096 • ACR Convergence 2021
The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study
Gabriella Maioli¹, Ennio Giulio Favalli², Elisa Pesce³, Martina Biggioggero², Mauro Bombaci³, Elena Agape², Martina Martinovic³, Tanya Fabbris³, Elena Zagato³, Andrea Favalli³, Andrea Gobbini³, Sergio Abrignani³, Renata Grifantini³ and Roberto Caporali⁴, ¹Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Milan, Italy, Milan, Italy, ²ASST Gaetano Pini-CTO Institute, Division of Clinical Rheumatology, Milan, Italy, Milan, Italy, ³Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy, ⁴Policlinico S. Matteo University, Pavia, Italy
Background/Purpose: Observational data have shown that rheumatic patients seem not to be more susceptible to SARS-CoV-2 infection neither to worse outcomes. However, the true prevalence…
Abstract Number: 0114 • ACR Convergence 2021
The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases
Jose A Gomez-Puerta¹, Núria Sapena², Juan C Sarmiento-Monroy³, Ana Belén Azuaga¹, Virginia Ruiz-Esquide², Beatriz Frade-Sosa², Marta Bassas², Rosa Morlà², Andrés Ponce², Juan D Cañete¹, Julio Ramirez², Anna Villella⁴, Antoni Trilla⁴ and Raimon Sanmarti⁵, ¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic, Barcelona, Spain, ³Hospital Clinic Barcelona, Barcelona, Spain, ⁴Department of Preventive Medicine and Epidemiology, Hospital Clínic, Barcelona, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: The best strategy for the prevention of SARS-CoV-2 infection is vaccination. Both mRNA and vector vaccines have demonstrated a satisfactory safety profile in general…
Abstract Number: 0528 • ACR Convergence 2021
Interferon Pathway Lupus Risk Alleles Modulate Risk of Death from Acute COVID-19
Ilona Nln¹, Ruth Fernandez Ruiz², Theresa Wampler Muskardin³, Stephanie Tuminello², Mukundan Attur², Eduardo Itturate², Christopher Petrilli², Steven B. Abramson⁴, Aravinda Chakravarti² and Timothy Niewold¹, ¹Colton Center for Autoimmunity NYU School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Type I interferon (IFN) is critical in our defense against viral infections. Increased type I IFN pathway activation is a genetic risk factor for…
Abstract Number: 0896 • ACR Convergence 2021
Systemic Lupus Erythematosus Disease Flares After SARS-CoV-2 Vaccination
Medha Barbhaiya¹, Jonah Levine¹, Caroline Siegel¹, Vivian Bykerk², Deanna Jannat-Khah¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Vaccination against SARS-CoV-2 is particularly important for patients with systemic lupus erythematosus (SLE), who may be at increased risk of hospitalization for COVID-19. However,…
Abstract Number: 1086 • ACR Convergence 2021
Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers
Mark Rudolph, Anja Kammensheidt and Roberta Alexander, Exagen Inc., Vista, CA
Background/Purpose: SARS-CoV-2 infection can lead to severe inflammation including increased complement activation (Ma, Kulkarni 2021) and the production of several proinflammatory cytokines. The rapid deployment…
Abstract Number: 1533 • ACR Convergence 2021
Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis
Claudia Marques¹, Ana Paula Reis², Adriana Kakehasi³, Edgard Neto⁴, Marcelo Medeiros Pinheiro⁵, Gecilmara Salviato Pileggi⁶, Gilda Ferreira⁷, Licia Maria Henrique Mota⁸, Odirlei Andre Monticielo⁹, Sandra Lúcia Ribeiro¹⁰, Felipe Omura¹¹, Adriana Marinho¹², Francinne Ribeiro¹³, Laurindo Rocha Jr¹⁴, Ana Silvia Martins¹⁵, Michel Yazbek¹⁶, Mariana Souza¹⁷, Nathália Sacilotto¹⁸, Samuel Shinjo¹⁹, Lilian Valadares²⁰, Ana Silva²¹, Danielle Christine de Brito²², Viviane de Souza²³, Carolina Costa²⁴, Samia Studart²⁵, Antônio Ximenes²⁶ and Ricardo Xavier²⁷, ¹Hospital das Clnicas - Universidade Federal de Pernambuco - UFPE, Recife, Brazil, ²Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁴UNIFESP, São Paulo, Brazil, ⁵Universidade Federal de São Paulo, São Paulo, Brazil, ⁶FACISB, Ribeirao Preto, Brazil, ⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁸Universidade de Brasília, Brasilia, Brazil, ⁹Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁰Universidade Federal do Amazonas, Amazonas, Brazil, ¹¹Clinica Omura, São Paulo, Brazil, ¹²FUNDHACRE, Rio Branco, Brazil, ¹³UERJ, Rio de Janeiro, Brazil, ¹⁴Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ¹⁵UFU, Uberlandia, MG, Brazil, ¹⁶UNICAMP, Campinas, Brazil, ¹⁷SCBH, Belo Horizonte, Brazil, ¹⁸Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, Brazil, ¹⁹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²⁰HOSPITAL GETULIO VARGAS, Recife, Brazil, ²¹UFG, GOIANIA, Goias, Brazil, ²²UFPB, Joao Pessoa, Brazil, ²³UFJF, JUIZ DE FORA, Brazil, ²⁴UFES, Vitoria, Brazil, ²⁵HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, ²⁶CLINICA CIP, Goiania, Brazil, ²⁷Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: The COVID-19 pandemic has brought uncertainties to the rheumatological practice, and despite the large number of publications to date, many questions remain unanswered. One…
Abstract Number: 1551 • ACR Convergence 2021
Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination
Tal Gazitt¹, Joy Feld², Amir Haddad³, Muna Elias⁴, Nizar Hijazi⁴, Nili Stein⁴, Victoria Furer⁵, Tali Eviatar⁶, Hagit Peleg⁷, Ori Elkayam⁸ and Devy Zisman⁴, ¹Carmel Hospital, Haifa, Israel, ²Carmel and Zvulun Medical Centre, Haifa, Israel, ³Carmel Medical Centre, Haifa, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel Aviv Sourasky Medical Center, Givataim, Israel, ⁷Hadassah Medical Center, Jerusalem, Israel, ⁸Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The rapid spread of the COVID-19 pandemic has created the need for mass vaccination of patients with autoimmune rheumatic disease (AIIRD) despite the lack…
Abstract Number: 1592 • ACR Convergence 2021
ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic
Tessa Englund¹, Saira Sheikh², Becki Cleveland¹, Emily McCormick¹, Crystal Schiller³ and Teresa Dickson¹, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease associated with significant symptom burden, including fatigue, anxiety, depression, pain, and negative impacts on health-related quality…
Abstract Number: 1609 • ACR Convergence 2021
SARS-CoV-2 Vaccination Willingness and Its Predictors in Patients with Chronic Inflammatory Rheumatic Diseases (CIRD)
Iulia Roman, Ioana Andreica, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Whether patients with chronic rheumatic diseases (CIRD) are at increased risk of developing severe COVID 19 infections is not entirely clear. However, some DMARDs…
Abstract Number: 1913 • ACR Convergence 2021
Patient Perceptions of Telemedicine Use in Rheumatology Clinics During the COVID-19 Pandemic: An Analysis from the COVID-19 Global Rheumatology Alliance
Mithu Maheswaranathan¹, Bruce Miller², Carly Harrison³, Rashmi Sinha⁴, Bugra Egeli⁵, Berk Degirmenci⁶, Emily Sirotich⁷, Rebecca Grainger⁸, Jonathan Hausmann⁹, Jean Liew¹⁰ and Yu Pei Eugenia Chock¹¹, ¹Duke University School of Medicine, Durham, NC, ²University of California San Diego School of Medicine, La Jolla, CA, ³LupusChat, Capitol Heights, MD, ⁴Systemic JIA Foundation, Cincinnati, OH, ⁵Boston Children's Hospital, Boston, MA, ⁶St. Elizabeth's Medical Center, Boston, MA, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Otago, Wellington, New Zealand, ⁹Beth Israel Deaconess Medical Center, Boston, MA, ¹⁰Boston University, Boston, MA, ¹¹Yale School of Medicine, Greenwich, CT
Background/Purpose: During the COVID-19 pandemic, healthcare systems rapidly expanded telemedicine to ensure continued access to care. Few studies have explored patient perceptions of the telemedicine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.